【ChiCTR2600133563】Contralesional rTMS targets and frequencies in subacute stroke with severely impaired upper limb: A Three-Arm pilot randomized control study
ChiCTR2600133563
尚未开始
/
/
/
2026-09-29
/
/
Ischemic and hemorrhagic stroke
Contralesional rTMS targets and frequencies in subacute stroke with severely impaired upper limb: A Three-Arm pilot randomized control study
Contralesional rTMS targets and frequencies in subacute stroke with severely impaired upper limb: A Three-Arm pilot randomized control study
Primary: To compare the effects of high-frequency rTMS over cPMd, cM1 and standard low-frequency rTMS over cM1, in addition to conventional rehabilitation, on upper-limb motor recovery in subacute stroke patients with severely impaired upper limb. Secondary: To evaluate the safety profile of high frequency contralesional rTMS in subacute stroke with upper limb severely impaired.
随机平行对照
其它
Computer-generated random sequence
Blind the participants
The trial is implemented entirely using existing institutional and service resources from Haven of Hope Hospital (Hospital Authority) in collaboration with The Hong Kong Chinese University (which provides academic support).
/
10
/
2026-10-01
2027-12-30
/
1.Adults aged 18–90 years with first-ever unilateral ischemic / hemorrhagic stroke 2.Subacute phase: 2 weeks to 3 months post-stroke 3.Severe upper-limb motor impairment: FMA-UE <= 28 points 4.Ability to provide written informed consent 5.Medically fit for TMS application by passing the safety screening questionnaire；
请登录查看1. TMS contraindications (e.g. metallic implant in head, pacemaker, brain electrodes) 2. Seizure history 3. unstable medical condition 4.severe aphasia or neglect or sensory loss preventing participation 5.Severe spasticity/ contracture (Modified Ashworth Scale >=3)；
请登录查看Haven of Hope Hospital
/
Haven of Hope Hospital的其他临床试验
Haven of Hope Hospital的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04